Veracyte, Inc.
VCYTStock
$59.22+135.78%52W
Market Cap$4.75B
P/E71.56x
Div yield—
Beta1.94
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)22.46%
Price vs S&P 500 (4W)16.27%
VGM Score61.49
Market Capitalization$4.75B
P/E Ratio (Annual)71.56x
Earnings Surprise History
Q1 260.35est. 0.15
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.11
4.21
4.22
4.22
Industry Peers — Health Services(29)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VCYTVeracyte, Inc. | D | A | A | $59.22 |
| NTRANatera, Inc. Common Stock | F | A | B | $269.83 |
| DGXQuest Diagnostics Inc. | C | D | C | $209.41 |
| LHLabcorp Holdings Inc. | C | D | C | $281.94 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $155.00 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | B | $128.18 |
| RDNTRadNet, Inc. Common Stock | D | C | C | $62.99 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | D | $16.48 |
| CELCCelcuity Inc. Common Stock | — | — | B | $88.29 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $71.96 |
About
Veracyte is a genomic diagnostics company providing molecular tests to help clinicians diagnose and treat cancer across multiple tumor types. Its portfolio includes Decipher tests for prostate and bladder cancer, Afirma for thyroid cancer, and Prosigna for breast cancer. These precision diagnostics enable informed clinical decision-making and improve patient outcomes at critical treatment junctures.